跳至主要内容
临床试验/NCT01580748
NCT01580748Unknown2 期

Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients

Seoul National University Bundang Hospital1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2012年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
25
试验地点
1
主要终点
change of CASA-Q score

研究概览

简要总结

There is currently no effective treatment of bronchiectasis other than treating its complications such as infection, bleeding, etc. Roflumilast is a newly developed anti-inflammatory drug that has proven to be effective in stable COPD. We hypothesized that Roflumilast might be effective in symptomatic bronchiectasis patients

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Bronchiectasis on CT
  • chronic (>3 months) cough or sputum

排除标准

  • needs hospitalization
  • life expectancy of less than six months
  • pregnancy or breast feeding
  • history of acute respiratory infection within 4 weeks
  • history of taking antibiotics within 4 weeks
  • active hemoptysis
  • %predicted FEV < 30%
  • severe liver disease (Child Pugh Class B or C)

研究组 & 干预措施

Treatment arm

Experimental

single arm study

干预措施: Roflumilast (Drug)

结局指标

主要结局

change of CASA-Q score

时间窗: 16 weeks

次要结局

  • alanine transaminase(4 weeks)
  • change of FEV1(16 weeks)
  • change of FVC(16 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hoil Yoon

Professor

Seoul National University Bundang Hospital

研究点 (1)

Loading locations...

相似试验

Phase2, Single Group, Open Clinical Trial to... | 临床试验